Close Menu

NEW YORK – GeneCentric Therapeutics and the Netherlands-based Erasmus University Medical Center said on Thursday that they are collaborating to identify RNA-based drug response markers and novel, targeted therapies for treating non-muscle invasive bladder cancer (NMIBC).

Under the research collaboration, North Carolina-based GeneCentric will use its Bladder Cancer Subtype Profiler tool to characterize the tumor, the patient's immune biology, and the tumor microenviroment. It may also use other novel assays to predict disease progression and drug response in these patients.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Sponsored by

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Sponsored by

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.